Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice

J Thulesen; B Hartmann; K J Hare; H Kissow; C Ørskov; Jens Juul Holst; S S Poulsen

doi:10.1136/gut.2003.035212

Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice

J Thulesen, B Hartmann, K J Hare, H Kissow, C Ørskov, Jens Juul Holst, S S Poulsen

93 Citations (Scopus)

Abstract

BACKGROUND: Glucagon-like peptide 2 (GLP-2) is an intestinotrophic mediator with therapeutic potential in conditions with compromised intestinal capacity. However, growth stimulation of the intestinal system may accelerate the growth of existing neoplasms in the intestine.

AIMS: In the present study, the effects of GLP-2 treatment on the growth of chemically induced colonic neoplasms were investigated.

METHODS: In 210 female C57bl mice, colonic tumours were initially induced with the methylating carcinogen 1,2-dimethylhydrazine (DMH) and mice were then treated with GLP-2. Two months after discontinuation of the carcinogen treatment, 135 of the mice were allocated to one of six groups which were treated twice daily with 25 microg GLP-2, 25 microg Gly2-GLP-2 (stable analogue), or phosphate buffered saline for a short (10 days) or long (one month) period. The remaining 75 mice had a treatment free period of three months and were then allocated to groups subjected to long term treatment, as above.

RESULTS: Colonic polyps developed in 100% of the mice, regardless of treatment. Survival data revealed no statistical significant differences among the different groups but histopathological analysis demonstrated a clear and significant increase in tumour load of mice treated with Gly2-GLP-2. The tumour promoting effect of native GLP-2 was less pronounced but the number of small sized polyps increased following long term treatment.

CONCLUSIONS: The present results clearly indicate that GLP-2 promotes the growth of mucosal neoplasms. Our findings highlight the need for future investigations on the effects of GLP-2 in conditions needing long time treatment or with increased gastrointestinal cancer susceptibility.

Original language	English
Journal	Gut
Volume	53
Issue number	8
Pages (from-to)	1145-1150
Number of pages	6
ISSN	0017-5749
DOIs	https://doi.org/10.1136/gut.2003.035212
Publication status	Published - Aug 2004

Keywords

Adenoma
Animals
Body Weight
Colonic Neoplasms
Colonic Polyps
Female
Glucagon-Like Peptide 2
Glucagon-Like Peptides
Intestinal Mucosa
Intestine, Small
Mice
Mice, Inbred C57BL
Organ Size
Peptides

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/gut.2003.035212

Cite this

@article{0ea548b9c16d495abf81ec0610a4a2b2,

title = "Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice",

abstract = "BACKGROUND: Glucagon-like peptide 2 (GLP-2) is an intestinotrophic mediator with therapeutic potential in conditions with compromised intestinal capacity. However, growth stimulation of the intestinal system may accelerate the growth of existing neoplasms in the intestine.AIMS: In the present study, the effects of GLP-2 treatment on the growth of chemically induced colonic neoplasms were investigated.METHODS: In 210 female C57bl mice, colonic tumours were initially induced with the methylating carcinogen 1,2-dimethylhydrazine (DMH) and mice were then treated with GLP-2. Two months after discontinuation of the carcinogen treatment, 135 of the mice were allocated to one of six groups which were treated twice daily with 25 microg GLP-2, 25 microg Gly2-GLP-2 (stable analogue), or phosphate buffered saline for a short (10 days) or long (one month) period. The remaining 75 mice had a treatment free period of three months and were then allocated to groups subjected to long term treatment, as above.RESULTS: Colonic polyps developed in 100% of the mice, regardless of treatment. Survival data revealed no statistical significant differences among the different groups but histopathological analysis demonstrated a clear and significant increase in tumour load of mice treated with Gly2-GLP-2. The tumour promoting effect of native GLP-2 was less pronounced but the number of small sized polyps increased following long term treatment.CONCLUSIONS: The present results clearly indicate that GLP-2 promotes the growth of mucosal neoplasms. Our findings highlight the need for future investigations on the effects of GLP-2 in conditions needing long time treatment or with increased gastrointestinal cancer susceptibility.",

keywords = "Adenoma, Animals, Body Weight, Colonic Neoplasms, Colonic Polyps, Female, Glucagon-Like Peptide 2, Glucagon-Like Peptides, Intestinal Mucosa, Intestine, Small, Mice, Mice, Inbred C57BL, Organ Size, Peptides",

author = "J Thulesen and B Hartmann and Hare, {K J} and H Kissow and C {\O}rskov and Holst, {Jens Juul} and Poulsen, {S S}",

year = "2004",

month = aug,

doi = "10.1136/gut.2003.035212",

language = "English",

volume = "53",

pages = "1145--1150",

journal = "Gut",

issn = "0017-5749",

publisher = "B M J Group",

number = "8",

}

TY - JOUR

T1 - Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice

AU - Thulesen, J

AU - Hartmann, B

AU - Hare, K J

AU - Kissow, H

AU - Ørskov, C

AU - Holst, Jens Juul

AU - Poulsen, S S

PY - 2004/8

Y1 - 2004/8

N2 - BACKGROUND: Glucagon-like peptide 2 (GLP-2) is an intestinotrophic mediator with therapeutic potential in conditions with compromised intestinal capacity. However, growth stimulation of the intestinal system may accelerate the growth of existing neoplasms in the intestine.AIMS: In the present study, the effects of GLP-2 treatment on the growth of chemically induced colonic neoplasms were investigated.METHODS: In 210 female C57bl mice, colonic tumours were initially induced with the methylating carcinogen 1,2-dimethylhydrazine (DMH) and mice were then treated with GLP-2. Two months after discontinuation of the carcinogen treatment, 135 of the mice were allocated to one of six groups which were treated twice daily with 25 microg GLP-2, 25 microg Gly2-GLP-2 (stable analogue), or phosphate buffered saline for a short (10 days) or long (one month) period. The remaining 75 mice had a treatment free period of three months and were then allocated to groups subjected to long term treatment, as above.RESULTS: Colonic polyps developed in 100% of the mice, regardless of treatment. Survival data revealed no statistical significant differences among the different groups but histopathological analysis demonstrated a clear and significant increase in tumour load of mice treated with Gly2-GLP-2. The tumour promoting effect of native GLP-2 was less pronounced but the number of small sized polyps increased following long term treatment.CONCLUSIONS: The present results clearly indicate that GLP-2 promotes the growth of mucosal neoplasms. Our findings highlight the need for future investigations on the effects of GLP-2 in conditions needing long time treatment or with increased gastrointestinal cancer susceptibility.

AB - BACKGROUND: Glucagon-like peptide 2 (GLP-2) is an intestinotrophic mediator with therapeutic potential in conditions with compromised intestinal capacity. However, growth stimulation of the intestinal system may accelerate the growth of existing neoplasms in the intestine.AIMS: In the present study, the effects of GLP-2 treatment on the growth of chemically induced colonic neoplasms were investigated.METHODS: In 210 female C57bl mice, colonic tumours were initially induced with the methylating carcinogen 1,2-dimethylhydrazine (DMH) and mice were then treated with GLP-2. Two months after discontinuation of the carcinogen treatment, 135 of the mice were allocated to one of six groups which were treated twice daily with 25 microg GLP-2, 25 microg Gly2-GLP-2 (stable analogue), or phosphate buffered saline for a short (10 days) or long (one month) period. The remaining 75 mice had a treatment free period of three months and were then allocated to groups subjected to long term treatment, as above.RESULTS: Colonic polyps developed in 100% of the mice, regardless of treatment. Survival data revealed no statistical significant differences among the different groups but histopathological analysis demonstrated a clear and significant increase in tumour load of mice treated with Gly2-GLP-2. The tumour promoting effect of native GLP-2 was less pronounced but the number of small sized polyps increased following long term treatment.CONCLUSIONS: The present results clearly indicate that GLP-2 promotes the growth of mucosal neoplasms. Our findings highlight the need for future investigations on the effects of GLP-2 in conditions needing long time treatment or with increased gastrointestinal cancer susceptibility.

KW - Adenoma

KW - Animals

KW - Body Weight

KW - Colonic Neoplasms

KW - Colonic Polyps

KW - Female

KW - Glucagon-Like Peptide 2

KW - Glucagon-Like Peptides

KW - Intestinal Mucosa

KW - Intestine, Small

KW - Mice

KW - Mice, Inbred C57BL

KW - Organ Size

KW - Peptides

U2 - 10.1136/gut.2003.035212

DO - 10.1136/gut.2003.035212

M3 - Journal article

C2 - 15247183

SN - 0017-5749

VL - 53

SP - 1145

EP - 1150

JO - Gut

JF - Gut

IS - 8

ER -

Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this